Kiniksa Pharmaceuticals International (NasdaqGS:KNSA) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsGeoff Meacham - Managing DirectorJohn Paolini - Chief Medical OfficerJonathan Kirshenbaum - Senior Manager of Investor RelationsJoyce Chang - Managing DirectorMark Ragosa - CFONick Lorusso - VP of Biotech Equity ResearchRoss Moat - COOSanj Patel - CEO and Chairman of the BoardConference Call ParticipantsEva Fortea - Executive Director and Senior Biotechnology AnalystRoger Song - Seni ...

Key Takeaways MEDX touched a new 52-week high, rising 49.9% from its $23.46 low.The ETF targets patented first-line pharma and biologics, charging 85 bps in fees.A 28.43 weighted alpha signals potential for further near-term gains.For investors seeking momentum, the Horizon Kinetics Medical ETF (MEDX) is probably on the radar now. The fund just hit a 52-week high and is up 49.9% from its 52-week low price of $23.46 per share.  But are there more gains in store for this ETF? Let’s take a quick look at the fu ...

Kiniksa Pharmaceuticals International (NasdaqGS:KNSA) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Speaker7Reminder, today's program is being recorded. Now I'd like to introduce your host for today's program, Jonathan Kirshenbaum, Investor Relations. Please go ahead, sir.Speaker3Thank you, operator. Good morning, everyone, and thank you for joining Kiniksa's call to discuss our fourth quarter and full year 2025 financial results and recent portfolio execution. A press release highlighting these resul ...

Apellis Pharmaceuticals (NasdaqGS:APLS) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Speaker13Morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals fourth quarter and full year 2025 earnings conference call. Please be advised that today's call is being recorded. I will now turn the call over to Eva Stroynowski, Head of Investor Relations. Please go ahead.Speaker9Good morning, and thank you for joining us to discuss Apellis's fourth quarter and full year ...

February 19, 2026 04:54 PM GMT Space | North America Varda Space: Space Manufacturing, Pharma Made in Orbit One day, your doctor's prescription may have been produced in the microgravity of space. The benefits of manufacturing complex compounds in space have been documented for decades, but never commercialized. Please note that we are reposting due to earlier technical issues with file size. Is the Space Economy about to get a pharmaceutical sector? Morgan Stanley does and seeks to do business with compani ...

Summary of Key Points from the Conference Call Industry Overview - The discussion revolves around global tariffs, particularly the implications of the Supreme Court ruling on the International Emergency Economic Powers Act (IEEPA) and its replacement with Section 122 tariffs. Core Insights and Arguments - **Tariff Levels**: Headline tariffs peaked in late 2025, with estimates indicating a reduction from approximately 13% to 11% due to the replacement of IEEPA with Section 122. Without Section 122, tariffs could fall to around 6-7% [6][12][27]. - **Complicated Path Ahead**: The path to higher tariffs is now more complex, with a risk skew towards lower tariffs, which supports expectations for lower US inflation in the second half of 2026 [6][10][29]. - **Sector vs. Country Tariffs**: The ruling suggests a shift from country-based tariffs to sector-based tariffs, which may have more legal grounding and could accelerate the tariff adjustment process [6][10][47]. - **Effective Tariff Rates**: The effective tariff rate remained subdued near 10%, and both nominal and effective rates are expected to decline post-IEEPA ruling [11][12][20]. Important but Overlooked Content - **Refunds Outlook**: The process for refunds related to tariffs remains unclear, with expectations that any refunds will be limited and delayed, potentially amounting to around $85 billion [31][30]. - **Bilateral Trade Agreements**: The ruling may not significantly alter existing bilateral agreements, as many countries are already facing lower tariff levels than before [32][66]. - **US-China Trade Relationship**: The US-China trade relationship is expected to remain stable, with a significant portion of tariffs tied to fentanyl and Section 301 investigations. Any reduction in IEEPA tariffs could be offset by increases in Section 301 tariffs [36][60]. - **Sector-Level Implications**: The transition to Section 122 tariffs is likely to reduce the dispersion in product-level tariffs, particularly benefiting consumer sectors, although the overall boost may be smaller than previously anticipated [68][69]. Conclusion - The Supreme Court ruling on IEEPA has significant implications for tariff structures, with a shift towards Section 122 tariffs expected to lower overall tariff levels and complicate future tariff adjustments. The focus on sector-based tariffs may provide a more stable framework moving forward, while the economic impact remains to be fully realized in the coming quarters.

February 23, 2026 09:00 PM GMT US Equity Strategy | North America US Equity Strategy: Institutional 13F Positioning - 4Q25 M | US Equity Strategy North America | Morgan Stanley & Co. LLC | | | --- | --- | --- | | | Equity Strategist | | | | Nick.Lentini@morganstanley.com | | | | Bas.Jaspers@morganstanley.com | | | | Michael J Wilson | | | | Equity Strategist | | | | M.Wilson@morganstanley.com | +1 212 761-2532 | | US investors added to Healthcare and reduced exposure to | Andrew B Pauker | | | | Equity Stra ...

Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound Proactive uses images sourced from Shutterstock The failure of its next-generation obesity drug to match Eli Lilly's blockbuster has blown a hole in Novo's post-Ozempic strategy, with analysts slashing price targets and two major banks walking away from bullish positions Novo Nordisk's (NYSE:NVO) last best hope for life after semaglutide has stumbled badly. The Danish drugmaker's CagriSema combination jab failed on Monday to ...

Investors in Inovio Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 7, 2026 to Discuss Your Rights - INO [Accessibility Statement] Skip NavigationNEW YORK, Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO).Shareholders who purchased shares of INO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not requi ...

Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027, in a bid to make the treatments more accessible to patients with insurance coverage. The obesity injection Wegovy, its new pill counterpart, the diabetes shot Ozempic and the oral diabetes drug Rybelsus will have a new lower list price of $675 per month starting on Jan. 1, 2027. The Wegovy medicines both currently have list prices of around $1,350 per mo ...